戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 2 mug HGF and 2 to 8 mug IGF-1) 30 min after coronary reperfusion.
2 tegies that can enhance timely and effective coronary reperfusion.
3 resolution is an early noninvasive marker of coronary reperfusion.
4  in preserving microvascular perfusion after coronary reperfusion.
5 e of myocardial salvage and viability during coronary reperfusion.
6  by which time 89% of patients had undergone coronary reperfusion.
7 eared to be safe but did not improve pre-PCI coronary reperfusion.
8                                              Coronary reperfusion after acute ST-elevation myocardial
9 tal administration of ticagrelor can improve coronary reperfusion and the clinical outcome is unknown
10  intracoronary alteplase infused early after coronary reperfusion associates with ischemic time.
11 ic therapy within 1 hour, and use of overall coronary reperfusion by 11% to 12% for patients with inf
12 nloading the left ventricle despite delaying coronary reperfusion during an acute MI reduces myocardi
13 about the clinical significance of HF in the coronary reperfusion era and the impact of its timing on
14 e salvage-dependent from salvage-independent coronary reperfusion in acute myocardial infarction and
15 m)Tc-N-NOET imaging to assess the success of coronary reperfusion in patients with acute myocardial i
16 tricular (LV) workload (LV unloading) before coronary reperfusion is emerging as a potential approach
17 ery centrifugal bypass system while delaying coronary reperfusion limits myocardial injury in a model
18       Early diagnosis and the most expedient coronary reperfusion method at each point of care: emerg
19                                   Suboptimal coronary reperfusion (no reflow) is common in acute coro
20 infarcting hearts with alternating cycles of coronary reperfusion/occlusion attenuates infarction, bu
21                                The impact on coronary reperfusion of crushed P2Y(12) inhibitor tablet
22 n A-antagonist administration at the time of coronary reperfusion preserves postischemic microvascula
23 n-specific thrombolytic regimens and improve coronary reperfusion rates in streptokinase-based regime
24  evidence demonstrating benefits from prompt coronary reperfusion, registries continue to show that m
25  recent years at the same time as the use of coronary reperfusion strategies has increased.
26 increasing use and success of interventional coronary reperfusion strategies, morbidity and mortality
27 ariables can define the risks of alternative coronary reperfusion therapies.
28 stablished before the introduction of modern coronary reperfusion therapy and secondary prevention st
29                               The success of coronary reperfusion therapy in ST-segment-elevation myo
30 essed their formation in patients undergoing coronary reperfusion via percutaneous transluminal coron
31                                              Coronary reperfusion was permitted 40 minutes after the
32 e, defined as the time from symptom onset to coronary reperfusion, was a pre-specified subgroup of in
33 ility as an index of oxidative stress during coronary reperfusion, we measured urinary levels by gas